5 results about "Active transport" patented technology

The application discloses a kind of pectinatocarpus selenium protein peptide and albumin peptide formula and preparation method, the core active ingredient of the formula is the selenium protein peptide of pectinatocarpus source and egg white albumin peptide, wherein the number average molecular weight of selenium protein peptide is 461Da, total selenium is 412.67mg / kg and selenocysteine and pectinatocarpus plant selenium peptide ratio is more than 90%, and the biological potency of albumin peptide is 94, and the molecular weight is 200-800Da;The application promotes active transport in intestinal tract by albumin peptide as carrier, and is prepared by combining dry granulation and tabletting process, the selenium absorption rate of the application is greatly improved, realizes the synergistic effect of hypoglycemic, hypolipidemic and antioxidant, and provides a new scheme for selenium supplement functional food.

The present disclosure provides a nanocomposite and a preparation method and use thereof. In the present disclosure, the nanocomposite is wrapped with Prussian blue nanoparticles (PB) using a platelet membrane (PM) as a shell; and a surface of the PM is modified with an aptamer of cancer cells and horseradish peroxidase (HRP). An ability of platelets (PLTs) to specifically target cancer cells and inflammatory sites can effectively enhance the accumulation of nanoparticles at tumor sites, and help PB better achieve a desirable photothermal therapy (PTT) under near-infrared light irradiation. In addition, hydrogen peroxide is highly expressed in the tumor microenvironment; the HRP modified on a surface of the nanocomposite can decompose the hydrogen peroxide to generate oxygen bubbles, which drive active transport of the nanocomposite, thereby enhancing the accumulation in cancer cells. Modification with the aptamer of cancer cells on a platelet membrane surface enhances cancer cell targeting.

The invention relates to the technical field of biomedicine, in particular to an organoid virus transfection method based on filter membrane mediation, which comprises the following steps: providing an organoid suspension which is mildly digested and retains part of matrigel; centrifuging in a container containing a microporous filter membrane, so that the organoid is flatly laid on the surface of the filter membrane to form a thin film; transferring the filter membrane bearing the organoid to an electric transfer device to be in contact with a virus vector, and applying an electric field to drive viruses to penetrate through the filter membrane and residual matrigel to enter cells; geometric shielding is eliminated through centrifugal tiling, and diffusion obstruction of matrigel is overcome through active transportation of electric field force; according to the method, the transfection efficiency and uniformity of the virus vector are remarkably improved on the premise of maintaining the integrity of the three-dimensional structure and high cell activity of the organoid, and the problem that the efficiency and the structure cannot be obtained at the same time in the prior art is solved.

An improved oral therapy delivery system with enhanced permeability, and an innovative method of manufacture. The therapy delivery system is comprised of a ternary, oil in water emulsion containing three (3) phases; a first aqueous phase that is hydrophilic, a second oil phase that is lipophilic, and a third activation or permeability enhancement phase. This three-phase construction allows delivery of both water soluble and oil soluble compounds, with increased activation of either or both. The third activation phase, in some embodiments, is comprised of 4 cellularly vital compounds capable of triggering active transport of material adjacent to cellular surfaces. These 4 compounds are vital for cellular functioning as incentives to trigger active transport of medicinal material.

The invention belongs to the technical field of biological medicines, and particularly relates to an efficient brain-targeted oxytocin nasal spray for resisting oxycodone addiction. The nasal spray comprises a polyelectrolyte complex formed by amino acid grafted chitosan and anionic polysaccharide, wherein oxytocin is loaded in the polyelectrolyte complex. The amino acid is selected from tryptophan, leucine or tyrosine. The preparation is administrated through a nasal cavity, the brain targeting property and bioavailability of oxytocin are remarkably improved by utilizing an LAT-1 transporter mediated active transport mechanism, and the preparation is used for preventing or treating addiction of opioid drugs such as oxycodone and the like. Experiments show that the preparation can significantly enhance distribution of oxytocin in the brain, inhibit formation and relapse of addiction and promote drug withdrawal, and has a good application prospect.